Identification of a novel splice-site mutation in the CYP1A2 gene

被引:53
作者
Allorge, D
Chevalier, D
Lo-Guidice, JM
Cauffiez, C
Suard, F
Baumann, P
Eap, CB
Broly, F
机构
[1] Fac Med Pole Rech, EA 2679, F-59045 Lille, France
[2] Fdn nant, Serv Psychogeriatr, CH-1804 Corsier Sur Vevey, Switzerland
[3] Hop Cery, Unite Biochim & Psychopharmacol, CH-1008 Prilly, Switzerland
关键词
CYP1A2; cytochrome P450; pharmacogenetics; polymorphism; splicing mutation;
D O I
10.1046/j.1365-2125.2003.01858.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To identify the molecular basis for a low CYP1A2 metabolic status, as determined by a caffeine phenotyping test, in a 71-year-old, nonsmoking, Caucasian woman who presented with very high clozapine concentrations despite being administered a standard dose of the drug. Methods The nucleotide sequence of the 7 exons, exon-intron boundaries and 5'-flanking region of the CYP1A2 gene was analysed by direct sequencing. Results Only one heterozygous point mutation was identified in the donor splice site of intron 6 (3534G > A) of CYP1A2. This mutation could cause abnormal RNA splicing and therefore lead to a truncated nonfunctional enzyme. No other carrier of this mutation was identified in a population of 100 unrelated healthy Caucasians. Conclusions This is the first report of a splice-site mutation affecting the CYP1A2 gene. This polymorphism is a likely explanation for the low CYP1A2 activity associated with high clozapine concentrations ill this patient.
引用
收藏
页码:341 / 344
页数:4
相关论文
共 22 条
[1]   Clozapine pharmacokinetics and pharmacodynamics studied with CYP1A2-null mice [J].
Aitchison, KJ ;
Jann, MW ;
Zhao, JH ;
Sakai, T ;
Zaher, H ;
Wolff, K ;
Collier, DA ;
Kerwin, RW ;
Gonzalez, FJ .
JOURNAL OF PSYCHOPHARMACOLOGY, 2000, 14 (04) :353-359
[2]   Very nigh cytochrome P4501A2 activity and nonresponse to clozapine [J].
Bender, S .
ARCHIVES OF GENERAL PSYCHIATRY, 1998, 55 (11) :1048-1050
[3]   CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST [J].
BERTILSSON, L ;
CARRILLO, JA ;
DAHL, ML ;
LLERENA, A ;
ALM, C ;
BONDESSON, U ;
LINDSTROM, L ;
DELARUBIA, IR ;
RAMOS, S ;
BENITEZ, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) :471-473
[4]  
BONDESSON U, 1988, PSYCHOPHARMACOLOGY, V95, P472
[5]   DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES [J].
BUTLER, MA ;
LANG, NP ;
YOUNG, JF ;
CAPORASO, NE ;
VINEIS, P ;
HAYES, RB ;
TEITEL, CH ;
MASSENGILL, JP ;
LAWSEN, MF ;
KADLUBAR, FF .
PHARMACOGENETICS, 1992, 2 (03) :116-127
[6]  
Chevalier D, 2001, Hum Mutat, V17, P355, DOI 10.1002/humu.48
[7]   Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population [J].
Chida, M ;
Yokoi, T ;
Fukui, T ;
Kinoshita, M ;
Yokota, J ;
Kamataki, T .
JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (09) :899-902
[8]   Organization of the CYP1A cluster on human chromosome 15:: implications for gene regulation [J].
Corchero, J ;
Pimprale, S ;
Kimura, S ;
Gonzalez, FJ .
PHARMACOGENETICS, 2001, 11 (01) :1-6
[9]   Will routine therapeutic drug monitoring have a place in clozapine therapy? [J].
Freeman, DJ ;
Oyewumi, LK .
CLINICAL PHARMACOKINETICS, 1997, 32 (02) :93-100
[10]   SIMPLE AND RELIABLE CYP1A2 PHENOTYPING BY THE PARAXANTHINE/CAFFEINE RATIO IN PLASMA AND IN SALIVA [J].
FUHR, U ;
ROST, KL .
PHARMACOGENETICS, 1994, 4 (03) :109-116